Posted by Michael Wonder on 22 Feb 2018
NICE sticks with ‘no’ for earlier use of Halaven
22 February 2018 - Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.
In a Final Appraisal Determination, the National Institute for Health and Care Excellence said the drug was too expensive for use in patients locally advanced or secondary breast cancer in adults who have had only one chemotherapy regimen.
Halaven (eribulin mesylate) increases overall survival by an average of 4.6 months compared with capecitabine, but it doesn’t increase the time during which the tumour doesn’t grow, it said.
